- Home
- HSCS vs TCBP Comparison
HSCS vs TCBP Comparison
Compare HSCS & TCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- TCBP
- Stock Information
- Founded
- HSCS 2007
- TCBP 2013
- Country
- HSCS United States
- TCBP United Kingdom
- Employees
- HSCS N/A
- TCBP 41
- Industry
- HSCS Medical Specialities
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSCS Health Care
- TCBP Health Care
- Exchange
- HSCS Nasdaq
- TCBP Nasdaq
- Market Cap
- HSCS 3.2M
- TCBP 3.3M
- IPO Year
- HSCS 2022
- TCBP 2022
- Fundamental
- Price
- HSCS $3.17
- TCBP $0.27
- Analyst Decision
- HSCS Strong Buy
- TCBP Strong Buy
- Analyst Count
- HSCS 2
- TCBP 1
- Target Price
- HSCS $13.50
- TCBP $2.40
- AVG Volume (30 Days)
- HSCS 15.1K
- TCBP 889.4K
- Earning Date
- HSCS 03-13-2025
- TCBP 11-25-2024
- Dividend Yield
- HSCS N/A
- TCBP N/A
- EPS Growth
- HSCS N/A
- TCBP N/A
- EPS
- HSCS N/A
- TCBP N/A
- Revenue
- HSCS $14,700.00
- TCBP N/A
- Revenue This Year
- HSCS $174.19
- TCBP N/A
- Revenue Next Year
- HSCS $4,100.00
- TCBP N/A
- P/E Ratio
- HSCS N/A
- TCBP N/A
- Revenue Growth
- HSCS 151.28
- TCBP N/A
- 52 Week Low
- HSCS $2.36
- TCBP $0.25
- 52 Week High
- HSCS $18.50
- TCBP $32.70
- Technical
- Relative Strength Index (RSI)
- HSCS 39.08
- TCBP 34.95
- Support Level
- HSCS $3.11
- TCBP $0.27
- Resistance Level
- HSCS $3.45
- TCBP $0.41
- Average True Range (ATR)
- HSCS 0.17
- TCBP 0.05
- MACD
- HSCS -0.02
- TCBP 0.02
- Stochastic Oscillator
- HSCS 8.70
- TCBP 31.19
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.